Butein (Chalcone · NF-kB/STAT3 Inhibitor · Senolytic Research)

Compound	Butein
Chemical class	Polyphenol — Chalcone (3,4,2′,4′-Tetrahydroxychalcone)
CAS	487-52-5
Primary source	Toxicodendron vernicifluum (Chinese lacquer tree), Rhus spp., Butea monosperma (flame of the forest)
Key applications	Anti-inflammatory, NF-κB/STAT3 inhibition, senolytic research
Claim strength	Moderate
Typical form	Research-grade isolate; Butea/Rhus extract
Buy from Herbuno	Fisetin 98% Powder (Wax Tree) | High-Purity Isolate | Rhus succedanea →

Name origin: From Butea monosperma (flame of the forest / Palash tree), a traditional Ayurvedic plant from which butein was early characterised. Also abundant in Toxicodendron vernicifluum (Chinese lacquer tree) and Rhus succedanea (wax tree) — the same botanical family as the plant used for Herbuno’s Fisetin 98% extract. Traditional use: Butea monosperma has extensive Ayurvedic use for inflammation, wound healing, liver disorders, and as an astringent. Butein has not been individually targeted in traditional practice but is a key bioactive in Butea bark and flower preparations. Research trajectory: Butein has attracted significant research for NF-κB and STAT3 dual inhibition (relevant to inflammatory and oncology contexts), anti-adipogenic effects, and most recently for senolytic activity — selectively clearing senescent cells. The senolytic application has been identified in the same research programmes investigating fisetin (a structurally related flavonol from the same botanical family). Commercial source: Rhus succedanea and related species are commercial sources for both butein and fisetin; they co-occur in wax tree heartwood. See sourcing options below.

---

Evidence for Butein Applications

NF-κB and STAT3 dual inhibition: Butein inhibits both NF-κB (upstream inflammatory kinase IKKβ) and STAT3 (JAK-STAT inflammatory/oncogenic pathway) at low micromolar concentrations. Dual pathway inhibition is mechanistically advantageous versus single-pathway inhibitors for chronic inflammatory conditions and oncology research contexts. Multiple cell-based studies confirm this dual activity. Claim strength: Moderate.

Senolytic activity: Butein has been identified in computational and cell-based screens as a senolytic agent — selectively inducing apoptosis in senescent cells while sparing normal proliferating cells. The mechanism involves dasatinib-like inhibition of senescent cell anti-apoptotic pathways (SCAPs). This places butein in the same emerging research space as quercetin and fisetin for longevity and healthy ageing formulations. Claim strength: Emerging (compelling mechanism; early preclinical).

Anti-adipogenic and metabolic: Butein inhibits adipocyte differentiation via PPAR-γ suppression and reduces lipid accumulation in hepatic cell models. Animal models of diet-induced obesity show modest but consistent metabolic improvements. Claim strength: Moderate.

---

Dosage & Formulator Specification

No established human clinical dose for butein. Preclinical effective concentrations: 10–50 µM in cell assays; animal anti-inflammatory and metabolic studies use 10–50 mg/kg oral doses. Human equivalent doses are speculative pending pharmacokinetic studies.

Butein is not commercially available as a standalone supplement ingredient at scale. It co-occurs with fisetin in Rhus species heartwood extracts but is not individually standardised in commercial fisetin products. For research formulation, isolated butein is available as an analytical standard (≥98% HPLC). Contact Herbuno for availability of butein-containing botanical extracts.

Butein has low aqueous solubility (chalcone class, logP ~2.6). Similar formulation considerations to isoliquiritigenin apply — lipid-based delivery or cyclodextrin complexation recommended. Susceptible to oxidative degradation; antioxidant co-formulation and nitrogen-flushed packaging advised.

---

Frequently Asked Questions — Butein

Is butein related to fisetin?
Butein (a chalcone) and fisetin (a flavonol) are structurally distinct compounds that share the same botanical family sources (Rhus/Toxicodendron species) and overlapping bioactivity profiles, including senolytic activity. Butein is the open-chain chalcone; fisetin is a ring-closed flavonol. Both share B-ring catechol and A-ring resorcinol hydroxylation patterns contributing to similar antioxidant and enzyme-interaction profiles.

What is the senolytic mechanism of butein?
Senescent cells upregulate pro-survival pathways (SCAP network) including BCL-2 family proteins, PI3K/AKT, and FOXO4 to resist apoptosis. Butein inhibits several of these pro-survival kinases, selectively tipping senescent cells toward apoptosis while normal cells — with lower SCAP dependence — are less affected. This is analogous to the dasatinib + quercetin combination mechanism studied in clinical senolytic trials.

Does the lacquer tree source raise any safety concerns for butein?
Toxicodendron vernicifluum is related to poison ivy and contains urushiol — a potent contact allergen. However, butein is typically extracted from the heartwood (not the sap), and properly processed heartwood extracts have urushiol removed. Formulators should require urushiol-negative certification for any Toxicodendron-derived extract before use in supplements or topical products.

Is butein or fisetin the better choice for a senolytic supplement?
Fisetin has the more developed clinical research trajectory for senolytic applications (Mayo Clinic trials) and better commercial availability. Butein’s senolytic evidence is earlier stage but mechanistically compelling. For current commercial formulation, fisetin is the more defensible primary senolytic active; butein is best positioned as an emerging co-ingredient or research reference compound.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery